- Home
- RNA vs BBIO Comparison
RNA vs BBIO Comparison
Compare RNA & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNA
- BBIO
- Stock Information
- Founded
- RNA 2012
- BBIO 2015
- Country
- RNA United States
- BBIO United States
- Employees
- RNA N/A
- BBIO N/A
- Industry
- RNA Biotechnology: Pharmaceutical Preparations
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- RNA Health Care
- BBIO Health Care
- Exchange
- RNA Nasdaq
- BBIO Nasdaq
- Market Cap
- RNA 5.5B
- BBIO 4.9B
- IPO Year
- RNA 2020
- BBIO 2019
- Fundamental
- Price
- RNA $45.28
- BBIO $23.36
- Analyst Decision
- RNA Strong Buy
- BBIO Strong Buy
- Analyst Count
- RNA 9
- BBIO 13
- Target Price
- RNA $63.22
- BBIO $46.83
- AVG Volume (30 Days)
- RNA 1.0M
- BBIO 1.4M
- Earning Date
- RNA 11-07-2024
- BBIO 11-12-2024
- Dividend Yield
- RNA N/A
- BBIO N/A
- EPS Growth
- RNA N/A
- BBIO N/A
- EPS
- RNA N/A
- BBIO N/A
- Revenue
- RNA $10,117,000.00
- BBIO $217,765,000.00
- Revenue This Year
- RNA $19.85
- BBIO $3,690.39
- Revenue Next Year
- RNA N/A
- BBIO N/A
- P/E Ratio
- RNA N/A
- BBIO N/A
- Revenue Growth
- RNA N/A
- BBIO 2209.77
- 52 Week Low
- RNA $5.68
- BBIO $21.62
- 52 Week High
- RNA $56.00
- BBIO $44.32
- Technical
- Relative Strength Index (RSI)
- RNA 48.69
- BBIO 42.78
- Support Level
- RNA $45.65
- BBIO $24.09
- Resistance Level
- RNA $56.00
- BBIO $27.57
- Average True Range (ATR)
- RNA 3.07
- BBIO 1.32
- MACD
- RNA 0.30
- BBIO -0.08
- Stochastic Oscillator
- RNA 31.59
- BBIO 14.93
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, acoramidis (AG10), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.